Nu.Q CAR T cells

**Nu.Q CAR T cells** are a form of chimeric antigen receptor T cell (CAR-T) therapy, an advanced immunotherapy modality in which a patient’s own T cells are genetically modified to express a synthetic receptor (CAR) that enables targeted recognition and killing of cancer cells. These engineered cells are expanded outside the body and then infused back to the patient to attack cells that express the designated antigen. CAR-T therapies have demonstrated transformative efficacy in hematologic malignancies, especially where standard therapies have failed. The precise antigen target and proprietary modifications of "Nu.Q CAR T cells" are not detailed in the available sources. The use of the "Nu.Q" name may indicate a novel target or platform but is not documented in peer-reviewed sources or US FDA approvals as of September 2025. The mechanism of action involves antigen-driven cytotoxicity via genetically modified autologous T lymphocytes. Developer and manufacturer names for Nu.Q CAR T cells are not confirmed in the literature. If this therapy is proprietary or investigational, further specificity on its molecular constructs, targets, and sponsors would be required for definitive description[1][5][10].

Brand names

Nu.Q CAR T cells

Other names

Nu.Q CAR T cells